Caroline Rosa Pellicciari
Research Subjects
Caroline Rosa Pellicciari has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Alberto Longui
Irmandade Santa Casa Misericordia Sao Paulo, Unidade Endocrinol Pediat, Sao Paulo, SP, Brazil
2 shared publications - Cristiane Kochi
Irmandade Santa Casa Misericordia Sao Paulo, Unidade Endocrinol Pediat, Sao Paulo, SP, Brazil
2 shared publications - Thiago Olivetti Artioli
Irmandade Santa Casa Misericordia Sao Paulo, Unidade Endocrinol Pediat, Sao Paulo, SP, Brazil
2 shared publications - Adriana Aparecida Siviero-Miachon
Universidade Federal de São Paulo, São Paulo SP, Brazil
1 shared publication - Ana Lúcia Torloni Gradinar
Irmandade Santa Casa de Misericórdia de São Paulo
1 shared publication Angela Maria Spinola e Castro
Pediatric Endocrinology Unit Federal University of Sao Paulo, UNIFESP Sao Paulo SP Brazil
1 shared publication
Latest Publications
- Open Access
- 20 May 2025
- Published by Wiley in Clinical Endocrinology
- Vol. 103 (3) , 327-337
The Use of miRNA Panel as a Growth Plate Marker of Short‐Term Response to GH
Introduction: Recombinant human growth hormone (GH) therapy shows variable growth responses in patients with growth hormone deficiency (GHD), highlighting the need for reliable biomarkers to predict individual sensitivity.Objective: This study investigated circulating microRNAs (miRNAs) involved in growth plate regulation during GH therapy in prepubertal children with GHD, aiming to establish a miRNA panel correlating with GH responsiveness.Patients and Methods: Sixteen patients were treated with daily recombinant GH (0.033 mg/kg) for 6 months. Two participants were excluded for protocol noncompliance, and one withdrew due to the spontaneous onset of puberty. Circulating levels of six miRNAs (miR‐22‐3p, miR‐30c‐5p, miR‐140‐5p, miR‐340‐5p, miR‐494‐3p, and miR‐16‐5p) were measured via digital PCR at baseline and at 1, 3, and 6 months of therapy. Clinical data (height, weight, growth velocity) and hormone levels were collected simultaneously.Results: All miRNAs displayed a characteristic response pattern: significant increases at 1 and 6 months, with a transient decline at 3 months. Despite these changes, no significant correlations were identified between miRNA levels and growth velocity, height SDS, or IGF‐1 levels. The study included treatment‐naïve patients and those with prior GH therapy following a 30‐day wash‐out period. While the treatment‐naïve group exhibited greater height‐SDS gains (p = 0.008), no differences in miRNA expression were observed between groups, nor was there a correlation between miRNA levels and height‐SDS increments.Conclusion: While this miRNA panel identified treatment‐responsive miRNAs, it did not correlate with growth outcomes. Increasing the sample size and incorporating additional miRNAs could enhance its clinical utility for predicting GH treatment sensitivity in GHD patients.Trial Registration: NCT05946915.
- 20 May 2025
- Published by Wiley in Clinical Endocrinology
- Vol. 103 (3) , 327-337
Open AccessThe Use of miRNA Panel as a Growth Plate Marker of Short‐Term Response to GH
Introduction: Recombinant human growth hormone (GH) therapy shows variable growth responses in patients with growth hormone deficiency (GHD), highlighting the need for reliable biomarkers to predict individual sensitivity.Objective: This study investigated circulating microRNAs (miRNAs) involved in growth plate regulation during GH therapy in prepubertal children with GHD, aiming to establish a miRNA panel correlating with GH responsiveness.Patients and Methods: Sixteen patients were treated with daily recombinant GH (0.033 mg/kg) for 6 months. Two participants were excluded for protocol noncompliance, and one withdrew due to the spontaneous onset of puberty. Circulating levels of six miRNAs (miR‐22‐3p, miR‐30c‐5p, miR‐140‐5p, miR‐340‐5p, miR‐494‐3p, and miR‐16‐5p) were measured via digital PCR at baseline and at 1, 3, and 6 months of therapy. Clinical data (height, weight, growth velocity) and hormone levels were collected simultaneously.Results: All miRNAs displayed a characteristic response pattern: significant increases at 1 and 6 months, with a transient decline at 3 months. Despite these changes, no significant correlations were identified between miRNA levels and growth velocity, height SDS, or IGF‐1 levels. The study included treatment‐naïve patients and those with prior GH therapy following a 30‐day wash‐out period. While the treatment‐naïve group exhibited greater height‐SDS gains (p = 0.008), no differences in miRNA expression were observed between groups, nor was there a correlation between miRNA levels and height‐SDS increments.Conclusion: While this miRNA panel identified treatment‐responsive miRNAs, it did not correlate with growth outcomes. Increasing the sample size and incorporating additional miRNAs could enhance its clinical utility for predicting GH treatment sensitivity in GHD patients.Trial Registration: NCT05946915.
- Open Access
- 11 October 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (6) , 815-822
Probiotic therapy outcomes in body composition of children and adolescent with obesity, a nonrandomized controlled trial
Objective: The objective of this study was to evaluate the impact of probiotic supplementation therapy on anthropometric values and body composition of children and adolescent with obesity. Subjects and methods: This is a nonrandomized controlled, prospective, double-blind interventional clinical trial with primary data analysis. The sample comprised 44 pubertal children and adolescent (8-17 years old) with obesity. The patients were allocated to probiotic (Lactobacillus rhamnosus) or placebo group, with matching of gender and chronological age. Both groups received nutritional [...] ABSTRACT Objective: The objective of this study was to evaluate the impact of probiotic supplementation therapy on anthropometric values and body composition of children and adolescent with obesity. Subjects and methods: This is a nonrandomized controlled, prospective, double-blind interventional clinical trial with primary data analysis. The sample comprised 44 pubertal children and adolescent (8-17 years old) with obesity. The patients were allocated to probiotic (Lactobacillus rhamnosus) or placebo group, with matching of gender and chronological age. Both groups received nutritional
- 11 October 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (6) , 815-822
Open AccessProbiotic therapy outcomes in body composition of children and adolescent with obesity, a nonrandomized controlled trial
Objective: The objective of this study was to evaluate the impact of probiotic supplementation therapy on anthropometric values and body composition of children and adolescent with obesity. Subjects and methods: This is a nonrandomized controlled, prospective, double-blind interventional clinical trial with primary data analysis. The sample comprised 44 pubertal children and adolescent (8-17 years old) with obesity. The patients were allocated to probiotic (Lactobacillus rhamnosus) or placebo group, with matching of gender and chronological age. Both groups received nutritional [...] ABSTRACT Objective: The objective of this study was to evaluate the impact of probiotic supplementation therapy on anthropometric values and body composition of children and adolescent with obesity. Subjects and methods: This is a nonrandomized controlled, prospective, double-blind interventional clinical trial with primary data analysis. The sample comprised 44 pubertal children and adolescent (8-17 years old) with obesity. The patients were allocated to probiotic (Lactobacillus rhamnosus) or placebo group, with matching of gender and chronological age. Both groups received nutritional
- Open Access
- 19 April 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (2) , 256-260
The impact of COVID-19 in children and adolescents with obesity in Brazil
Objective: The primary goal of the study was to evaluate weight gain in children and adolescents with obesity during the COVID-19 pandemic period, and compare it with the period before the pandemic. Subjects and methods: The sample comprised 68 children with obesity aged between 7 and 18 years, 30 (44.1%) boys and 38 (55.9%) girls, who were attended at the pediatric endocrinology clinic of the Irmandade da Santa Casa de Misericórdia de São Paulo, SP, Brazil. Weight gain in [...] ABSTRACT Objective: The primary goal of the study was to evaluate weight gain in children and adolescents with obesity during the COVID-19 pandemic period, and compare it with the period before the pandemic. Subjects and methods: The sample comprised 68 children with obesity aged between 7 and 18 years, 30 (44.1%) boys and 38 (55.9%) girls, who were attended at the pediatric endocrinology clinic of the Irmandade da Santa Casa de Misericórdia de São Paulo, SP, Brazil. Weight gain in
- 19 April 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (2) , 256-260
Open AccessThe impact of COVID-19 in children and adolescents with obesity in Brazil
Objective: The primary goal of the study was to evaluate weight gain in children and adolescents with obesity during the COVID-19 pandemic period, and compare it with the period before the pandemic. Subjects and methods: The sample comprised 68 children with obesity aged between 7 and 18 years, 30 (44.1%) boys and 38 (55.9%) girls, who were attended at the pediatric endocrinology clinic of the Irmandade da Santa Casa de Misericórdia de São Paulo, SP, Brazil. Weight gain in [...] ABSTRACT Objective: The primary goal of the study was to evaluate weight gain in children and adolescents with obesity during the COVID-19 pandemic period, and compare it with the period before the pandemic. Subjects and methods: The sample comprised 68 children with obesity aged between 7 and 18 years, 30 (44.1%) boys and 38 (55.9%) girls, who were attended at the pediatric endocrinology clinic of the Irmandade da Santa Casa de Misericórdia de São Paulo, SP, Brazil. Weight gain in